Torrent Pharmaceuticals Q1 Results FY27: Uniresearch Predictions, Analyst Views and Key Watchpoints

The Torrent Pharmaceuticals Q1 Results FY27 outlook is anchored on Q4 FY26 verified actuals from consolidated quarterly financial data and Uniresearch analysis applying the 28-analyst FY27 consensus to Q1 FY26 verified actuals. Uniresearch projects Q1 Results FY27 Revenue at Rs 4,309 Cr (+35.6% YoY) and PAT at Rs 627 Cr (+14.4% YoY). Prepared by Kunal Singla.

Click Here – Get Free Investment Predictions

Torrent Pharmaceuticals Q1 Results FY27 – Uniresearch Prediction

Metric	Q1 FY26 Actual	Q1 Results FY27 Uniresearch Prediction	YoY Change	Source
Torrent Pharmaceuticals Revenue (Rs Cr)	3,178	4,309	+35.6%	Uniresearch | 28-analyst consensus applied to Q1 FY26 verified actual
PAT (Rs Cr)	548	627	+14.4%	Uniresearch | 28-analyst consensus applied to Q1 FY26 verified actual
Avg Analyst Target	Rs 4,879	12-month view	–	Analyst consensus (28 analysts)

Torrent Pharmaceuticals Q1 Results FY27 predictions apply analyst consensus FY27 growth rates (Revenue: +35.6%, PAT: +14.4%, 28 analysts) to Q1 FY26 verified actuals. Not guaranteed outcomes. No assumptions by Univest.

Torrent Pharmaceuticals Q1 Results FY27: Q4 FY26 Key Metrics

Metric	Q4 FY26 Actual	YoY Change	Source
Revenue (Rs Cr)	4,197	+41.8% YoY	Consolidated quarterly financial data
PAT (Rs Cr)	364	-26.9% YoY	Consolidated quarterly financial data

Q4 FY26 actuals from consolidated quarterly financial data. Q1 Results FY27 actuals for these metrics will be confirmed when results are declared.

What Analysts Are Saying About Torrent Pharmaceuticals Q1 Results FY27

Across 28 analysts covering Torrent Pharmaceuticals, the consensus projects FY27 revenue growth of +35.6% and profit growth of +14.4%, with an average 12-month price target of Rs 4,879. The Torrent Pharmaceuticals Q1 Results FY27 prediction of Rs 627 Cr PAT and Rs 4,309 Cr Revenue is derived from this consensus applied to verified Q1 FY26 actuals.

Key Watchpoints for the Torrent Pharmaceuticals Q1 Results FY27

Revenue Delivery vs Consensus

The primary watchpoint for the Torrent Pharmaceuticals Q1 is whether Q1 Results FY27 Revenue delivers in line with Uniresearch’s Rs 4,309 Cr projection, based on the 28-analyst consensus FY27 revenue growth of +35.6%. Q1 FY26 base was Rs 3,178 Cr.

PAT and Margin Performance

The Torrent Pharmaceuticals Q1 Results FY27 PAT watchpoint is whether Q1 Results FY27 achieves Rs 627 Cr as projected by Uniresearch (PAT consensus: +14.4% growth from Q1 FY26 base of Rs 548 Cr). Q4 FY26 PAT was Rs 364 Cr for context.

Risks to the Torrent Pharmaceuticals Q1 Uniresearch Prediction

Below-Consensus Revenue Growth

If Q1 Results FY27 revenue comes in below the +35.6% consensus growth rate, actual revenue would fall short of the Torrent Pharmaceuticals projection of Rs 4,309 Cr. Sector-specific demand conditions and macro factors are the primary variables.

PAT Pressure from Costs or Provisions

The Torrent Pharmaceuticals Q1 PAT prediction of Rs 627 Cr could be impacted by cost escalation, increased provisions or one-time charges in Q1 Results FY27 that are not factored into the 28-analyst consensus growth rate of +14.4%.

Q4 FY26 Baseline Behind the Torrent Pharmaceuticals Prediction

The Torrent Pharmaceuticals Q1 consensus prediction uses Q1 FY26 actuals (Revenue Rs 3,178 Cr, PAT Rs 548 Cr) as the base. Q4 FY26 actuals were Revenue Rs 4,197 Cr (+41.8% YoY) and PAT Rs 364 Cr (-26.9% YoY) per consolidated quarterly financial data.

Torrent Pharmaceuticals: Conclusion

The Torrent Pharmaceuticals Q1 Uniresearch prediction of Revenue Rs 4,309 Cr and PAT Rs 627 Cr is derived from the 28-analyst consensus FY27 growth rates applied to verified Q1 FY26 actuals – with no assumptions by Univest. When Torrent Pharmaceuticals are declared, investors can benchmark actual performance against this consensus prediction. Track live updates on Univest for Q1 Results FY27 alerts.

Track Torrent Pharmaceuticals Live on the Univest Screener

Stay updated on Torrent Pharmaceuticals analyst ratings and Q1 Results FY27 alerts on Univest.

Download the Univest iOS App or Univest Android App for live Torrent Pharmaceuticals Q1 alerts.

Frequently Asked Questions on Torrent Pharmaceuticals

What is Uniresearch’s PAT prediction for Torrent Pharmaceuticals Q1 Results FY27?

Ans. Uniresearch projects Torrent Pharmaceuticals Q1 Results PAT at Rs 627 Cr, derived by applying the 28-analyst FY27 profit growth consensus of +14.4% to Q1 FY26 verified PAT of Rs 548 Cr. Not a Univest estimate.

What is the Revenue prediction for Torrent Pharmaceuticals Q1 Results FY27?

Ans. Uniresearch projects Torrent Pharmaceuticals Q1 Results Revenue at Rs 4,309 Cr, derived by applying the 28-analyst FY27 revenue growth consensus of +35.6% to Q1 FY26 verified Revenue of Rs 3,178 Cr from consolidated quarterly financial data.

What were Torrent Pharmaceuticals Q1 Results FY27?

Ans. Q4 FY26 consolidated Revenue was Rs 4,197 Cr (+41.8% YoY) and PAT was Rs 364 Cr (-26.9% YoY) per consolidated quarterly financial data.

Does the Torrent Pharmaceuticals Q1 Results FY27 article contain Univest estimates?

Ans. No. The Torrent Pharmaceuticals Q1 Results predictions are derived from the 28-analyst analyst consensus growth rates applied to verified Q1 FY26 actuals. Univest makes no independent projections.

What is the average analyst target price in the Torrent Pharmaceuticals Q1 Results FY27?

Ans. The 28-analyst consensus gives an average 12-month price target of Rs 4,879 for Torrent Pharmaceuticals, as cited in the Torrent Pharmaceuticals Q1 Results prediction article.

What are the risks to the Torrent Pharmaceuticals Q1 Results FY27 prediction?

Ans. The primary risks to the Torrent Pharmaceuticals Q1 Results Uniresearch prediction are: below-consensus revenue growth (target: +35.6%) and PAT pressure from unexpected cost escalation or provisions impacting the +14.4% PAT consensus.

What is the Q1 FY26 base for the Torrent Pharmaceuticals Q1 Results FY27?

Ans. Q1 FY26 consolidated Revenue was Rs 3,178 Cr and PAT was Rs 548 Cr per consolidated quarterly financial data. These verified actuals form the base to which the 28-analyst consensus is applied to derive the Torrent Pharmaceuticals Q1 Results prediction.